Optimi Health Completes First Production of Novel MDMA Drug Candidate OPTI-MHCL
February 06, 2023 08:30 ET
|
Optimi Health Corp.
The Company is producing OPTI-MHCL in-house under its Health Canada issued Dealers Licence using Optimi’s scalable, proprietary production method. Optimi is also manufacturing MDMA under...
Alberta Puts Patients First By Regulating Psychedelic Therapy: Optimi Health
October 06, 2022 12:51 ET
|
Optimi Health Corp.
Highlights: The safe supply of psychedelic drug products manufactured at a GMP-level is critical in treating serious mental health issues. Minister of Mental Health and Addictions, the Honourable...
Optimi Health Provides Progress Report On Year Of Commercialization
September 01, 2022 09:00 ET
|
Optimi Health Corp.
Company set to introduce psychedelic product catalogue showcasing in-house EU-GMP manufacturing expertise VANCOUVER, British Columbia, Sept. 01, 2022 (GLOBE NEWSWIRE) -- Optimi Health Corp. (CSE:...
Optimi Health Enters Into International Collaborative Research and Supply Agreement With Promises Innovative Recovery Center
August 30, 2022 09:00 ET
|
Optimi Health Corp.
VANCOUVER, British Columbia, Aug. 30, 2022 (GLOBE NEWSWIRE) -- Optimi Health Corp. (CSE: OPTI) (OTCQX: OPTHF) (FRA: 8BN) (“Optimi” or the “Company”), a Canadian-based company licensed by Health...
Optimi Health Signs Psilocybin Supply Agreement With Halucenex Life Sciences Inc.
May 27, 2022 09:00 ET
|
Optimi Health Corp.
VANCOUVER, British Columbia, May 27, 2022 (GLOBE NEWSWIRE) -- Optimi Health Corp. (CSE: OPTI) (OTCQX: OPTHF) (FRA: 8BN) (“Optimi” or the “Company”), a homegrown, Canadian company producing natural,...